[HTML][HTML] Utilization of immunotherapy for the treatment of hepatocellular carcinoma in the peri-transplant setting: transplant oncology view
Simple Summary Hepatocellular carcinoma is the second most common cause of cancer-
related deaths and accounts for over eighty percent of primary liver cancers worldwide …
related deaths and accounts for over eighty percent of primary liver cancers worldwide …
[HTML][HTML] Timeline of FDA-approved targeted therapy for cholangiocarcinoma
Simple Summary Cholangiocarcinoma constitutes around 3% of gastrointestinal cancers,
and mortality from this cancer has been rising in the recent decades. Many cases of …
and mortality from this cancer has been rising in the recent decades. Many cases of …
[HTML][HTML] Immunotherapy as a neoadjuvant therapy for a patient with hepatocellular carcinoma in the pretransplant setting: a case report
Systemic combination therapy of immune checkpoint inhibitors and vascular endothelial
growth factors have provided the basis for improved outcomes in select patients with …
growth factors have provided the basis for improved outcomes in select patients with …
[HTML][HTML] Gemcitabine and cisplatin as neo-adjuvant for cholangiocarcinoma patients prior to liver transplantation: case-series
Background: The management of cholangiocarcinoma is continually reviewed on a current
evidence basis to develop practice guidelines and consensus statements. However, the …
evidence basis to develop practice guidelines and consensus statements. However, the …
“Transplantomics” for predicting allograft rejection: real-life applications and new strategies from Network Medicine
G Benincasa, M Viglietti, E Coscioni, C Napoli - Human Immunology, 2023 - Elsevier
Although decades of the reductionist approach achieved great milestones in optimizing the
immunosuppression therapy, traditional clinical parameters still fail in predicting both acute …
immunosuppression therapy, traditional clinical parameters still fail in predicting both acute …
[HTML][HTML] Immune checkpoint inhibitors for solid tumors in the adjuvant setting: current progress, future directions, and role in transplant oncology
Simple Summary Immune checkpoint inhibitors (ICIs) are being increasingly used after
primary treatment of early-stage tumors to treat any residual disease and prevent …
primary treatment of early-stage tumors to treat any residual disease and prevent …
[HTML][HTML] Gemcitabine plus cisplatin versus non-gemcitabine and cisplatin regimens as neoadjuvant treatment for cholangiocarcinoma patients prior to liver …
Background: Cholangiocarcinoma management is constantly being updated in view of
existing evidence in order to establish practice guidelines and consensus statements …
existing evidence in order to establish practice guidelines and consensus statements …
[HTML][HTML] Transplant Oncology: An Emerging Discipline of Cancer Treatment
Simple Summary Transplant oncology is an evolving treatment ideal for patients suffering
from various cancers with poor prognoses. The concept essentially is the complete removal …
from various cancers with poor prognoses. The concept essentially is the complete removal …
[HTML][HTML] Cell-Free DNA as a Surveillance Tool for Hepatocellular Carcinoma Patients after Liver Transplant
Simple Summary The liver is the world's sixth most common primary tumor site, accountable
for nearly 5% of all cancers and over 8% of cancer-related deaths. Hepatocellular carcinoma …
for nearly 5% of all cancers and over 8% of cancer-related deaths. Hepatocellular carcinoma …
[HTML][HTML] The Diagnostic, Prognostic, and Therapeutic Potential of Cell-Free DNA with a Special Focus on COVID-19 and Other Viral Infections
G Hovhannisyan, T Harutyunyan… - International Journal of …, 2023 - mdpi.com
Cell-free DNA (cfDNA) in human blood serum, urine, and other body fluids recently became
a commonly used diagnostic marker associated with various pathologies. This is because …
a commonly used diagnostic marker associated with various pathologies. This is because …